Combination revascularization therapy using peripheral mononuclear cell and adrenomedullin for patients with peripheral artery disease
Project/Area Number |
23591053
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Circulatory organs internal medicine
|
Research Institution | University of Miyazaki |
Principal Investigator |
|
Project Period (FY) |
2011-04-28 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 循環器 / 再生医療 / アドレノメデュリン / 末梢血単核球移植術 / 臨床 / 末梢動脈疾患 / 末梢血単核球移植 / 血管再生 / 血管新生 |
Outline of Final Research Achievements |
We assessed effectiveness of combination therapy that consisted with therapeutic revascularization using peripheral mononuclear cells and continuous infusion of adrenomedullin (AM) (1.5 pmol/kg/min X 8 hr/day for 2 weeks) for severe ischemic limb of patients with peripheral artery disease who had not responded to conventional therapy. We conducted a randomized, double-blind, placebo-controlled trial. Four patients, 2 with AM and 2 with placebo, were treated and one patient in each group was followed over 1 year. Favorable effect was continued for 1 year and 6 months in patient with AM. In placebo group, 1 patient sustained therapeutic effect for 1 year, but another 1 patient underwent foot amputation within several months. We cannot conducted enough evaluation from small number of the patients, but we collected valuable experience and knowledge through the trial, and the information is contributed as a base of the plan in investigator initiated trials using AM which is now in progress.
|
Report
(5 results)
Research Products
(6 results)